Kiniksa (KNSA) CFO Exercise and Sale Disclosed in Form 4
Rhea-AI Filing Summary
Michael R. Megna, Chief Accounting Officer of Kiniksa Pharmaceuticals International (KNSA), reported multiple equity transactions from September 1–3, 2025. The filings show a series of restricted share unit (RSU) grants, option exercises and open-market trades executed pursuant to a 10b5-1 plan. On September 3, 2025 the reporting person exercised a share option for 11,000 Class A Ordinary Shares at an exercise price of $17.92 and sold 11,000 shares in the market at a weighted average price of $34.84. Several RSU awards and stock options were granted or recognized on September 1–2, 2025 with various vesting schedules; one option grant has an exercise price of $33.49 and expires August 31, 2035. Following the reported transactions the reporting person beneficially owned 38,011 Class A Ordinary Shares.
Positive
- Full disclosure of transactions including exercise prices, weighted average sale price, and vesting schedules
- Use of a 10b5-1 trading plan is explicitly disclosed, indicating pre-arranged trading intent
- Detailed vesting terms for RSUs and options are provided, clarifying future equity dilution timing
Negative
- None.
Insights
TL;DR: Routine insider exercise and sale under a 10b5-1 plan; not unusually dilutive or unexpected.
The form indicates a typical pattern where an insider exercises vested options at $17.92 and immediately sells the underlying shares at a higher market price via a pre-established 10b5-1 plan. The sale of 11,000 shares at a weighted average of $34.84 realized a spread versus the exercise price, while the filing also documents newly recognized RSUs and an option grant with a $33.49 exercise price expiring in 2035. These transactions are descriptive of compensation monetization and standard equity compensation administration rather than extraordinary corporate events.
TL;DR: Transactions follow standard governance practices with a disclosed 10b5-1 plan and documented vesting terms.
The report clearly discloses the reporting persons relationship to the issuer as Chief Accounting Officer and shows use of a 10b5-1 trading plan executed July 24, 2024. Vesting schedules for multiple RSU grants and option vesting commencement dates are specified, and the option exercised on September 3, 2025 is noted as fully vested where applicable. Disclosure meets Section 16 reporting norms and provides necessary vesting and expiration details for oversight.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Share Option | 11,000 | $0.00 | -- |
| Exercise | Class A Ordinary Share | 11,000 | $17.92 | $197K |
| Sale | Class A Ordinary Share | 11,000 | $34.84 | $383K |
| Exercise | Restricted Share Unit | 774 | $0.00 | -- |
| Exercise | Class A Ordinary Share | 774 | $0.00 | -- |
| Tax Withholding | Class A Ordinary Share | 375 | $34.28 | $13K |
| Grant/Award | Restricted Share Unit | 10,575 | $0.00 | -- |
| Grant/Award | Share Option | 21,150 | $0.00 | -- |
| Exercise | Restricted Share Unit | 2,363 | $0.00 | -- |
| Exercise | Restricted Share Unit | 2,557 | $0.00 | -- |
| Exercise | Restricted Share Unit | 3,933 | $0.00 | -- |
| Exercise | Class A Ordinary Share | 2,363 | $0.00 | -- |
| Exercise | Class A Ordinary Share | 2,557 | $0.00 | -- |
| Exercise | Class A Ordinary Share | 3,933 | $0.00 | -- |
| Tax Withholding | Class A Ordinary Share | 4,282 | $33.49 | $143K |
Footnotes (1)
- Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on July 24, 2024. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $34.80 and $35.005. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2025. The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2025. The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date, September 1, 2024. The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2023. The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2022. The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 2, 2021. The option is fully vested and Exercisable.
